## ADPT: Adaptive Biotechnologies Corporation - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 0.57 indicates fundamental undervaluation. Consistent execution (4/4 quarters beat estimates).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($15.37)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 1
- **Sentiment:** Bullish (Bullish: 1, Bearish: 0)

**1. Adaptive Biotechnologies (ADPT) Is Up 10.1% After New Pfizer TCR-AI Collaboration Milestone Deal - What's Changed**
- Source: Simply Wall Street | 20251221T110918 | Bullish | Relevance: 100%
- Adaptive Biotechnologies (ADPT) saw a 10.1% rise in its stock after announcing two non-exclusive agreements with Pfizer. These collaborations involve applying Adaptive's T-cell receptor discovery platform to rheumatoid arthritis and licensing its TCR-antigen binding dataset for Pfizer's AI-driven drug discovery, with potential milestones up to US$890 million. The deals emphasize the commercial value of Adaptive's immune repertoire data and offer a new perspective on its investment narrative amid ongoing profitability challenges.

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 1 ($0.16M) |
| Sells | 14 ($10.79M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 52.9% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 4 / 5 |

**Top Holders:**
- Viking Global Invest: 19.7% (0.0%)
- Blackrock Inc.: 8.8% (-2.3%)
- Vanguard Group Inc: 7.4% (-0.0%)
- Ameriprise Financial: 3.9% (+84.3%)
- Sumitomo Mitsui Trus: 2.4% (-15.1%)

### Key Risks

1. High beta (2.20) amplifies market volatility - any risk-off move could trigger sharp selloff.
2. Heavy insider selling: $11M sold (14 transactions in 90 days).
3. Elevated short interest (8.7%): bears positioning against stock.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Momentum building: MRS_20 improving +7.1% over 5 days suggests accumulation.

### Fundamentals

PEG ratio 0.57 indicates undervaluation relative to growth. Balance sheet: strong liquidity (3.4x). Insider selling cluster ($10.8M in 90 days), potential headwind. Institutional flow bullish (4 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $2.7B |
| Beta | 2.20 |
| 52W Range | $5.91 - $20.76 |
| Short Interest | 8.7% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.57 |
| Forward P/E | N/A |
| Current P/E | N/A |
| YoY Growth | N/A |
| EPS Direction | None |

### Technicals

MRS_20 strengthening from -5.9% to 1.1% (+7.1% in 5 days), confirming momentum buildup. Below STRENGTH zone by 2.9pp (needs >4.0% for momentum thesis). MRS_5 at 3.5% confirms short-term momentum alignment. Full SMA alignment bullish (above 20/50/200 SMAs). RSI neutral at 57. OFD pattern: +MLL (Support).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 1.14% (CS: 59) | Neutral |
| RSI_14 | 57.0 | Neutral |
| MACD Histogram | 0.06 | Bullish |
| vs SMA20 | 1.018x | Above |
| vs SMA50 | 1.053x | Above |
| vs SMA200 | 1.444x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $17.41
- **Stop Loss:** $15.37 (11.7% risk)
- **Target:** $21.49 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 588
- **Position Value:** $10,237.08
- **Portfolio %:** 10.24%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 120% | L2 100% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.20x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with improving risk appetite. VIX decline to 52-week lows and moderate breadth recovery suggest calming conditions, though narrow participation indicates selectivity remains key. Positive earnings momentum and AI adoption themes provide fundamental support for quality growth names.*

### Earnings

**Next:** 2026-02-10 (Est: $-0.18)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $-0.14 | $0.06 | +143.3% |
| 2025Q2 | $-0.24 | $-0.17 | +28.6% |
| 2025Q1 | $-0.31 | $-0.20 | +35.5% |
| 2024Q4 | $-0.24 | $-0.23 | +5.2% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*